PM
Prosight Management Portfolio holdings
AUM
$580M
Turnover
39.22%
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
-1.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$210M
AUM Growth
-$22.7M
(-9.8%)
Cap. Flow
+$4.13M
Cap. Flow
% of AUM
1.97%
Top 10 Holdings %
Top 10 Hldgs %
48.59%
Holding
65
New
13
Increased
16
Reduced
18
Closed
18
Avg Time Held Equity + Options
0.8
years
Top 10 Avg Time Held Equity + Options
0.4
years
Top 20 Avg Time Held Equity + Options
0.9
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cue Biopharma
CUE
|
+$7.68M |
| 2 |
Aurinia Pharmaceuticals
AUPH
|
+$7.29M |
| 3 |
Baxter International
BAX
|
+$6.69M |
| 4 |
Prothena Corp
PRTA
|
+$6.56M |
| 5 |
MTCR
Metacrine, Inc. Common Stock
MTCR
|
+$5.31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kura Oncology
KURA
|
+$12.8M |
| 2 |
Arrowhead Research
ARWR
|
+$4.93M |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$4.28M |
| 4 |
Aldeyra Therapeutics
ALDX
|
+$3.41M |
| 5 |
Vericel Corp
VCEL
|
+$2.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.06% |
| 2 | Technology | 4.31% |
| 3 | Miscellaneous | 3.63% |
| 4 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
CALL
Evolus
EOLS
$488M
| – | – |
-37,400
| Closed | -$198K | – |
|
|
52
Evolus
EOLS
$488M
| – | – |
-281,541
| Closed | -$1.49M | – |
|
53
Immunovant
IMVT
$5.82B
| – | – |
-95,500
| Closed | -$2.33M | – |
|
54
DELISTED
ModivCare
MODV
| – | – |
-14,923
| Closed | -$1.18M | – |
|
55
NeoGenomics
NEO
$2.17B
| – | – |
-38,819
| Closed | -$1.2M | – |
|
56
Pacira BioSciences
PCRX
$1.45B
| – | – |
-55,000
| Closed | -$2.89M | – |
|
57
Personalis
PSNL
$1.7B
| – | – |
-188,750
| Closed | -$2.45M | – |
|
58
United Therapeutics
UTHR
$23.4B
| – | – |
-15,000
| Closed | -$1.81M | – |
|
|
59
Vericel Corp
VCEL
$2.05B
| – | – |
-209,897
| Closed | -$2.9M | – |
|
60
Xeris Biopharma Holdings
XERS
$1.84B
| – | – |
-419,469
| Closed | -$1.12M | – |
|
|
ONEM
61
PUT
DELISTED
1Life Healthcare
ONEM
| – | – |
-8,000
| Closed | -$291K | – |
|
|
LHCG
62
DELISTED
LHC Group LLC
LHCG
| – | – |
-4,509
| Closed | -$786K | – |
|
|
TPTX
63
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| – | – |
-25,602
| Closed | -$1.65M | – |
|
|
MGLN
64
DELISTED
Magellan Health Services, Inc.
MGLN
| – | – |
-5,200
| Closed | -$379K | – |
|
|
ZGNX
65
PUT
DELISTED
Zogenix, Inc.
ZGNX
| – | – |
-8,200
| Closed | -$221K | – |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q3 2020 Portfolio in Review
As of Q3 2020, Prosight Management held 65 positions worth $210M, down 9.8% from $233M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Prosight Management's Q3 2020 filing shows 13 new, 16 increased, 18 reduced and 18 closed positions. Its largest new stake was Prothena Corp: 545,195 shares worth $5.45M. The largest sale was Kura Oncology, an estimated $12.8M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Technology and Miscellaneous.
- Prosight Management's largest Q3 2020 buy was Prothena Corp: 545,195 shares worth $5.45M.
- Prosight Management added most to Cue Biopharma in Q3 2020, an estimated $7.68M increase.
- Prosight Management's biggest Q3 2020 reduction was Kura Oncology, cutting an estimated $12.8M.
- Prosight Management fully exited Arrowhead Research in Q3 2020, selling an estimated $4.93M.
- Prosight Management's ten largest holdings make up 49% of its $210M portfolio in Q3 2020.
- Prosight Management opened 13 new positions and closed 18 in Q3 2020.
- Prosight Management's portfolio value fell 9.8% quarter-over-quarter to $210M.
Based on Prosight Management's 13F filing for Q3 2020, filed 13 Nov 2020.